Kiniksa Pharmaceuticals International, Plc · NASDAQ:KNSA
Kiniksa Pharmaceuticals International — Q3 2026 Earnings Presentation
14 slides from Kiniksa Pharmaceuticals International's earnings presentation, Oct 27, 2026
Slide 1: Third Quarter 2026 Financial Results and Recent Portfolio Execution
Third Quarter 2026 Financial Results and Recent Portfolio Execution OCTOBER 27, 2026
Slide 2: Agenda
Agenda Introduction | Sanj K. Patel, Chief Executive Officer ARCALYST® Commercial Execution | Ross Moat, Chief Operating Officer Third Quarter 2026 Financial Results | Mark Ragosa, Chief Financial Officer Closing Remarks | Sanj K. Patel, Chief Executive Officer Q&A Session 2
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements with respect to Kiniksa Pharmaceuticals International, plc (and its consolidated subsidiaries, collectively, unless context oth
Slide 4: Introduction
Introduction Sanj K. Patel Chief Executive Officer
Slide 5: Q3 2026 Business Highlights
Q3 2026 Business Highlights Driving ARCALYST Maintaining Financial Advancing Clinical Portfolio Revenue Strength Q3 2026 ARCALYST revenue KPL-387 pivotal Phase 3 trial, Strong financial position of $286.0M PASTORALE, enrolling & with ~$569M in cash dosing patients Continued growth potential Current
Slide 6: Expanding Adoption of IL-1α & IL-1β Inhibition Driving ARCALYST Sales
Expanding Adoption of IL-1α & IL-1β Inhibition Driving ARCALYST Sales Increased penetration of multiple recurrence patient population to ~23% as of the end of Q3 2026 Year-Over-Year Net Revenue Growth Total and Repeat Prescribers of ARCALYST for Recurrent Pericarditis Patients $286.0M >5,450 ~1,625
Slide 7: 2026 ARCALYST Net Product Sales Guidance $1.045-1.050B
2026 ARCALYST Net Product Sales Guidance Revenue guidance raised to $1.045-$1.050B from $980-$995M $1.045-1.050B Expected Net Product Sales Position ARCALYST as 2nd line Standard of Care $677.6M Deepen penetration into 2+ recurrence population $417.0M Drive adoption among larger 1st recurrence $233.
Slide 8: ARCALYST Commercial Execution
ARCALYST Commercial Execution Ross Moat Chief Operating Officer
Slide 9: Opportunity for ARCALYST Growth Remains High Across RP Population
Opportunity for ARCALYST Growth Remains High Across RP Population Commercial success to date validates investments that are expanding reach and frequency to more patients % of Physicians Considering ARCALYST by Recurrence1 % of Physicians Putting ARCALYST Before Corticosteroids1 (n= 200 Cardiologist
Slide 10: Heart's Home DTC Campaign is Showing Strong Signals of Success
Heart’s Home DTC Campaign is Showing Strong Signals of Success Market Research Findings1 Website Activity Improvements2 • ~20% of patients recall seeing the ARCALYST ad since its • 12x increase in weekly visits to ARCALYST.com relative to launch pre-DTC period • >50% of patients seeing the ad indica
Slide 11: Financials
Third Quarter 2026 Financials Mark Ragosa Chief Financial Officer
Slide 12: Third Quarter 2026 Financial Results
Third Quarter 2026 Financial Results Three Months Ended September 30, Income Statement Three Months Ended September 30, Collaboration Expenses1 2026 2025 2026 2025 ARCALYST Net Sales $286.0M $180.9M Product Revenue $286.0M $180.9M Profit Split-Eligible Cost of Goods Sold ($26.2M) ($20.0M) License an
Slide 13: Closing Remarks
Closing Remarks Sanj K. Patel Chief Executive Officer
Slide 14: Third Quarter 2026 Financial Results and Recent Portfolio Execution
Third Quarter 2026 Financial Results and Recent Portfolio Execution OCTOBER 27, 2026
Kiniksa Pharmaceuticals International — Q3 2026 Earnings Presentation on 6ix